GERAKAN BERANI VAKSIN COVID-19 BERSAMA LION AIR GROUP

Anita Sukarno, Ratna Dewi, Ety Nurhayati, Budi Mulyana, Kiki Amanda Fatmawati

Sari


The Covid-19 pandemic has had a negative impact on every aspect of Indonesian life. The Covid-19 vaccine has been created and its distribution has proceeded progressively, especially in Indonesia. The Indonesian government has launched a massive use of the Covid-19 vaccine and it is hoped that approximately 118 million Indonesians have succeeded in getting the vaccine. This is carried out with an effort to create community immunity (herd immunity) in every community in order to break the chain of spread of Covid-19. Lion Air Group is a company engaged in air transportation that demands human movement. In order for this mobilization need to work, the Lion Air Group participates in the success of the Indonesian government's program in eradicating Covid-19 through a vaccination program. Thus, the air transportation mode is no longer a threat to the community so that the circulation of mobilization needs continues. The potential group as the target of this activity is the entire workforce of the Lion Air Group. The method of carrying out the activity is by injecting the Sars-Cov 2 (Sinovac) vaccine with a dose of 0.5 ml in the muscular deltoid area of the left. This activity takes place for 10 days each in March and April 2021 in collaboration with the Ministry of Health and mandated Health Workers. This activity succeeded in targeting 15,733 (Phase 1) and 14,233 (Phase II) participants. Thus, the implementation of the vaccination activity can be a scourge in the creation of herd immunity.

 

Keywords: Covid-19, herd immunity, vaccine 

Teks Lengkap:

PDF

Referensi


Daftar Pustaka

Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020). A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 5(1), 237. https://doi.org/10.1038/s41392-020-00352-y

Dror, A. A., Eisenbach, N., Taiber, S., Morozov, N. G., Mizrachi, M., Zigron, A., Srouji, S., & Sela, E. (2020). Vaccine hesitancy: the next challenge in the fight against COVID-19. European Journal of Epidemiology, 35(8), 775–779. https://doi.org/10.1007/s10654-020-00671-y

Kementerian Kesehatan Republik Indonesia. (2020). Paket Advokasi Vaksinasi Covid-19 Lindungi Diri, Lindungi Negeri. https://promkes.kemkes.go.id/paket-advokasi-vaksinasi-covid-19-lindungi-diri-lindungi-negeri

Palacios, R., Patiño, E. G., de Oliveira Piorelli, R., Conde, M. T. R. P., Batista, A. P., Zeng, G., Xin, Q., Kallas, E. G., Flores, J., Ockenhouse, C. F., & Gast, C. (2020). Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. In Trials (Vol. 21, Issue 1, p. 853). https://doi.org/10.1186/s13063-020-04775-4

Poudel, K., & Subedi, P. (2020). Impact of COVID-19 pandemic on socioeconomic and mental health aspects in Nepal. International Journal of Social Psychiatry, 66(8), 748–755. https://doi.org/10.1177/0020764020942247

Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., Wang, L., Zhao, G., Ding, Y., Zhao, Y., & Yin, W. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious Diseases. https://doi.org/10.1016/S1473-3099(20)30987-7

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., … Qin, C. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science (New York, N.Y.), 369(6499), 77–81. https://doi.org/10.1126/science.abc1932

Kementerian Kesehatan Republik Indonesia. (2020). Paket Advokasi Vaksinasi Covid-19 Lindungi Diri, Lindungi Negeri. https://promkes.kemkes.go.id/paket-advokasi-vaksinasi-covid-19-lindungi-diri-lindungi-negeri

Ma, W.-X., & Ran, X.-W. (2020). [The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 51(2), 146–150. https://doi.org/10.12182/20200360606

Menteri Dalam Negeri. (2021). Pedoman Umum Menghadapi Pandei Covid-19 Bagi Pemerintah Daerah: Pencegahan, Pengendalian, Diagnosis dan Manajemen. Menteri Dalam Negeri. https://www.kemendagri.go.id/documents/covid-19/BUKU_PEDOMAN_COVID-19_KEMENDAGRI.pdf

Palacios, R., Patiño, E. G., de Oliveira Piorelli, R., Conde, M. T. R. P., Batista, A. P., Zeng, G., Xin, Q., Kallas, E. G., Flores, J., Ockenhouse, C. F., & Gast, C. (2020). Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. In Trials (Vol. 21, Issue 1, p. 853). https://doi.org/10.1186/s13063-020-04775-4

Poudel, K., & Subedi, P. (2020). Impact of COVID-19 pandemic on socioeconomic and mental health aspects in Nepal. International Journal of Social Psychiatry, 66(8), 748–755. https://doi.org/10.1177/0020764020942247

Roper, R. L., & Rehm, K. E. (2009). SARS vaccines: where are we? Expert Review of Vaccines, 8(7), 887–898. https://doi.org/10.1586/erv.09.43

Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., Liang, H., Bao, L., Xu, Y., Ding, L., Zhou, W., Gao, H., Liu, J., Niu, P., Zhao, L., … Yang, X. (2020). Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell, 182(3), 713-721.e9. https://doi.org/10.1016/j.cell.2020.06.008

World Health Organization. (2021). Coronavirus. https://www.who.int/health-topics/coronavirus#tab=tab_3

Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., Wang, L., Zhao, G., Ding, Y., Zhao, Y., & Yin, W. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious Diseases. https://doi.org/10.1016/S1473-3099(20)30987-7

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., & Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious Diseases, 21(2), 181–192. https://doi.org/10.1016/S1473-3099(20)30843-4

Zhang, Y., Zeng, G., Pan, H., Li, C., Kan, B., Hu, Y., Mao, H., Xin, Q., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Gong, X., Qin, C., Hu, Y., Liu, X., Cui, G., … Zhu, F. (2020). Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. MedRxiv, 2020.07.31.20161216. https://doi.org/10.1101/2020.07.31.20161216




DOI: https://doi.org/10.47007/abd.v8i01.4783

Refbacks

  • Saat ini tidak ada refbacks.


Lembaga Penerbitan Universitas Esa Unggul
Jalan Arjuna Utara No 9 Kebon Jeruk Jakarta 11510
Telp : 021 5674223 ext 266

email : [email protected]

 

Web Analytics View My Stats